1. In Vivo
  2. >>Global Vision

Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

 
• By David Wild

South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.

Primary Care Physicians Could Soon Use Retinal Images To Detect Systemic Diseases • Source: Shutterstock

It has been the stuff of science fiction for years: a digital scanner screens a person for minute physiological changes, right in the comfort of their home. The device instantaneously detects a disease at its earliest stage, or even before it appears, thus fending off ill health. Now, a body of research and advances in artificial intelligence are bringing that vision closer to reality, with retinal scanning algorithms that can predict the risk of ophthalmic, cardiovascular, and renal diseases.

“The eye is the only organ that shows blood vessels directly in a non-invasive way,” Kevin Choi, co-founder and CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.